Learn the latest trends in applying physiologically based pharmacokinetic (PBPK) modeling to accelerate early drug discovery and enhance confidence in pre-IND decision-making.
Our PBPK experts discuss:
- Trends in Drug Discovery: Learn how PBPK modeling is being adopted earlier in the drug development process to triage best drug candidates, support first-in-human PK prediction, assess potential drug-drug interaction and formulation risks, and more.
- Simcyp® Discovery Version 2: Certara’s advanced PBPK platform for pre-IND success introduces major updates to improve usability, automation, and model development. Updates include:
- Automation and Documentation Enhancements: New workflow tools such as the Dose Finding Tool streamline and speed up model development and help identify optimal dosing strategies to meet PK/PD targets.
- Structure-Based Predictors: Use SMILES strings to predict key physicochemical properties.
- Expanded Static DDI Capabilities: Inclusion of Desipramine (CYP2D6 substrate) and Paroxetine (competitive and mechanism-based CYP2D6 inhibitor) in the static DDI tool.
- Performance Upgrades: Enhanced user experience with GPT-powered ‘Ask Simcyp’ help and new Simcyp Cloud simulation services.
- Usability Improvements: Realtime reporting of simulation results within the Simulator, improved user experience.
Whether you’re a new or experienced user, this session provides practical insights on how to integrate Simcyp Discovery into your preclinical workflows and stay at the forefront of model-informed drug development.
